Stryker, the medical-device maker, reported third-quarter profit that beat forecasts on stronger margins, but its shares sank regardless. Illumina, the gene-sequencing company, also beat its Q3 2026 estimates, and its shares fell after hours too. MasTec, the infrastructure construction firm, saw an earnings miss offset a revenue beat and closed down 3% the same session.
Contrast that with MIAX, the options exchange operator, which beat its Q3 2026 EPS forecast and saw its shares rise after hours — the more conventional reaction investors expect when a company tops expectations.
The pattern across these four reports shows that an EPS or revenue beat alone did not determine which way a stock moved this session. Something else — likely forward guidance, margin trajectory, or demand commentary that the earnings slides don't fully spell out in the material reviewed — drove the divergence. None of the wire items specify exactly what in Stryker's or Illumina's outlook triggered the selling, despite the headline beats.
What remains unresolved is the specific guidance language behind each move. Until full transcripts or analyst notes detail what forward commentary spooked Stryker and Illumina holders, the gap between a reported beat and the stock's reaction is the more informative number than the beat itself.